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INTRODUCTION
While the application of gold in medicine dates back to several thousand years, research into gold-based drugs has recently seen a renaissance. 1 Within this research area, organometallic gold complexes have been particularly explored as anticancer therapeutics, mainly due to their higher stability in physiological conditions guaranteed by the presence of a direct Au-C bond. [1] [2] In this context, Au III complexes stabilized by C^N cyclometalated ligands represent a versatile class of organometallics which have found several applications due to their unique physicochemical properties 3 that have been the subject of a number of investigations. [4] [5] [6] Also intensely investigated are the applications of these complexes in the field of bioinorganic medicinal chemistry. 2, [7] [8] [9] Indeed, the superior stabilization of the gold(III) ion against reduction in aqueous solution, granted by C^N cyclometalated ligands with respect to, for example, N^N chelating ones, gave new impetus to the search of possible alternatives to platinum(II)-based anticancer agents. The first examples of cyclometalated Au III complexes as potential anticancer agents were those based on the C^N ligand 2-(N,N-dimethylamino)methylphenyl. [10] [11] Those complexes displayed higher cytotoxic activity than cisplatin against human cancer cells in vitro and antitumor activity comparable to the Pt(II) anticancer drug cisplatin in vivo. [10] [11] Following these successful results, a number of other cyclometalated Au III complexes supported by C^N chelates as well as by C^N^N, N^C^N and C^N^C pincer ligands, endowed with promising anticancer properties and unique mechanisms of action, have been reported. 2, [7] [8] [9] 12 These complexes also present the advantage of tolerating a large palette of ancillary ligands such as phosphanes, [13] [14] NHCs, 15 and N-donor ligands, 16 enabling optimization of their biological properties. In general, for such different families of gold(III) cyclometalated compounds, interactions with protein targets are considered to be responsible for their observed anticancer effects, 9, [17] [18] whereas interactions with DNA seem less relevant, with a few exceptions. [19] [20] Within this research area, several years ago some of us reported the synthesis and biological activity of the hydroxo complex [Au(bipy . 23 The three compounds manifest rather similar chemical properties being stable in solution and moderately active in cancer cells. [22] [23] Reactions with proteins lead to formation of different amounts of metalated adducts, as evidenced by mass spectrometry, where a single {Au(bipy dmb -H)} fragment is invariably linked to the protein. 23 The choice of coumarins was motivated by their pharmacological activities, including anticancer activity, 24 and for their photophysical properties. Coumarin fluorochromes are small and biocompatible, and are widely used for in vivo and in vitro diagnostics and imaging. [25] [26] As for saccharine, it was supposed to confer higher water solubility to the resulting complex and aspects of the biological profile of a number of saccharinate Au I and Au III complexes were investigated by some of us. 27 Thio-β-D-glucose tetraacetate is the ancillary ligand of the antiarthritic drug auranofin, the latter recently being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections. 28 Thus, this moiety has been widely used as ancillary ligand in a variety of metal-based drugs, due to its capability to facilitate uptake into cancer cells by modulating the lipophilic/hydrophilic character, as well as via possible interaction with GLUT1 transporters. [29] [30] Finally, the tripeptide glutathione is ubiquitous in cells where it exerts many roles: it acts as an antioxidant, a free radical scavenger and a detoxifying agent. Heavy metal ions are mainly removed by GSH after coordination to the thiol group. However, studies also postulated the role of GSH adduct formation in the mechanisms of toxicity of cisplatin; 31 thus, the design of metal-GSH complexes could be exploited as a strategy to increase the anticancer effects of experimental metallodrugs. This notwithstanding, well defined GSH metal complexes are still rare. [32] [33] [34] Thus, the new compounds were studied for spectroscopic properties, as well as for their antiproliferative effects in a small panel of human cancer cell lines and against nontumorigenic cells from embryonic kidney (HEK-293) in vitro. In order to characterize the compounds with biological nucleophiles, some of the most cytotoxic derivatives were studied for their reactivity with the model protein cytochrome c (cyt c) and mixtures of amino acids by Electrospray Ionization Mass Spectrometry (ESI MS). Furthermore, capillary zone electrophoresis (CZE)-ESI MS allowed to determine the preference for the compounds'
binding to a single strand oligonucleotide (5´-dATTGGCAC-3´) in competition experiments with the model protein ubiquitin (ub). 35 For the first time, we observed some of the Au III C^N^N compounds to display remarkable affinity for nucleic acid binding, which may pave the way to the exploitation of these organometallic scaffolds to selectively target DNA structures.
RESULTS AND DISCUSSION

Synthesis and Characterization
The eight new cyclometalated Au III compounds 2-PF6 to 9-PF6, of general formula [Au(bipy H} NMR spectra ( Figure S13 ), only the alkynyl derivative was formed also in the case of the gold(I) complex 10.
Acetonitrile solutions of all the new Au I/III complexes 1Cl-PF6, 1OH-PF6, 1OMe-PF6, 2-PF6 -9-PF6 and 10 feature peculiar UV-Vis absorption bands in the region between 220 and 350 nm (Table S1 ). An analysis of the absorption spectra recorded on solutions at (ii) The absorption bands in the range 240-330 nm, in many cases overlapped by the more intense UV absorption (see above), can be envisaged in the electronic spectra of the ligands and can be therefore attributed to interligand (IL) transitions.
(iii)
All Au III complexes display a band, featuring a maximum in the range 320-330 nm, at energies lower than those of the lowest energy bands of the relevant ligands. This band is significantly red-shifted to 410 nm in 4-PF6 ( Figure 2 ). In agreement to previous theoretical results 36 and to what was previously proposed for 1Cl-PF6 and 1OH-PF6, 21 this band features a partial Ligand-to-Metal Charge-Transfer (LMCT) character. 
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The emission properties of the synthesized complexes were measured at r.t. in acetonitrile solution (Table S1) (Table S1) [Au(C2ArNHCOQ)(PPh3)], 10, the structure in the solid state was solved by X-ray diffraction analysis (see Table S2 for crystallographic details). X-ray quality crystals were obtained by slow diffusion of diethyl ether into a dichloromethane solution of complexes 2-PF6 and 10 and into an acetonitrile solution of complexes 3-PF6 and 6-PF6. ORTEP views of 2-PF6, 3-PF6 and 6-PF6 with the atom labelling schemes are shown in Figure 3 and selected bond lengths and angles collected in 
Antiproliferative Properties
The antiproliferative properties were assessed by monitoring the ability of the investigated gold complexes to inhibit cell growth using the classical MTT assay as described in the Experimental section. Initially, the compounds were tested against human lung epithelial cancer (A549) and human ovarian cancer (SKOV-3) cancer cells. (Table S4) .
Thus, the most effective compounds 3-PF6 and 5-PF6 were evaluated in other cell lines, including human breast cancer (MCF-7), human melanoma (A375), and the non-tumorigenic human embryonic kidney (HEK-293) cells. The resulting EC50 values are shown in Table 1 and compared to those of cisplatin and of the free ancillary ligand of complex 3-PF6,
HC2ArNHCOQ
. In general, compound 3-PF6 behaves similarly to cisplatin in the A549 and SKOV-3 cell lines. Instead, 5-PF6 is a far better inhibitor of cell proliferation than cisplatin, leading to the hypothesis that the compound may be active via different mechanisms.
Unfortunately, while 3-PF6 is scarcely toxic against the non-tumorigenic HEK-293 cells, 5-PF6
shows scarce selectivity.
It should be noted that the observed differences in antiproliferative effects may be due to various reasons, including the stability of the compounds in aqueous solution, as well as 21, 22 However, in order to further explore the differences among the biological properties of the compounds, we have studied the stability of the most active complexes 3-PF6 and 5-PF6 in comparison to the one of the least cytotoxic analogue 6-PF6 (see Table S4 ) by UV-visible spectrophotometry. Figure S23 shows the representative absorption spectra of the two complexes 5-PF6 and 6-PF6 recorded in PBS (pH 7.4) at different times over 24 h. As it can be observed, complex 5-PF6 is perfectly stable during time Figure S23B ). The stability of 5-PF6 in the presence of the intracellular reducing agent glutathione (GSH) has also been studied by UVVis spectrophotometry ( Figure S24 ), and the results shows that the compound is able to form adducts with GSH right after mixing the two components. 
Mass spectrometry
Reaction with cytochrome c, cysteine and histidine
Investigating the stability and ligand exchange reactions of putative metallodrugs is important Table 2 and Figure 5 . The lack of reactivity of 6-PF6 with biomolecules, together with its pronounced instability, may also be responsible for its scarce cytotoxicity against cancer cells. Table 3 ). The unreacted cation of 1OH-PF6 was found at all three incubation time points with the highest intensities at 10 min ( Figure 6 ). All the analytes were baseline-separated in time by CZE. After 10 min the bis-adduct gave the highest product signal intensities, whereas after 6 h the tris-adduct showed the most intense peak. Thus, the DNA oligomer seems to feature three stable binding sites on the nucleotides, which are kinetically favored over amino acid binding.
Overall, these results show the pronounced reactivity of the compound with oligonucleotides with respect to peptides and amino acids. 
Conclusions
The synthesis of a new series of (C^N^N) cyclometalated Au III complexes featuring the 6-(1,1-dimethylbenzyl)-2,2'-bipyridine) scaffold has been reported and the compounds have been characterized via different methods, including some by X-ray diffraction. All the complexes were studied for their absorption and photophysical properties, showing typical IL and MLCT absorption bands in the UV-Vis region, while they feature a main emission band centred around 350 nm which is largely attributable to the bipy dmb ligand. Unfortunately, the photoactive ancillary ligands quench their fluorescence upon binding to the Au III centre, most likely due to an ISC relaxation path favoured by the gold metal ion.
The compounds were evaluated for their antiproliferative properties in vitro and their activity was shown to be highly dependent on the nature of the ancillary ligand. Specifically, both Au III complexes 3-PF6 and 5-PF6, featuring coumarin ligands, showed the most pronounced anticancer activity, although 5-PF6 displayed scarce selectivity towards cancer cells with respect to non-tumorigenic ones. In the future, the selectivity of the compound may be improved tethering it to targeting peptides via derivatization of the cyclometalated scaffold. [Au(bipy (2800). Emission spectrum, (λem nm) = 434.
X-Ray crystallography
Crystals of 2-PF6, 3-PF6, and 10 were examined using a Xcalibur Oxford Diffraction diffractometer equipped with CCD area detector and mirror-monochromated Mo Kα radiation (λ = 0.71073 Å). Crystals of 6-PF6 were examined using a Bruker Apex II diffractometer, equipped with a CCD area detector and graphite-monochromated Cu Kα radiation (λ = 1.54178 Å). Intensities were integrated from data recorded on 1° (2-PF6, 3-PF6 and 10) or 1.5°
(6-PF6) frames by ω or φ rotation. Cell parameters were refined from the observed positions of all strong reflections in each data set. Analytical (2-PF6, 3-PF6 and 10) or multi-scan (6-PF6) absorption correction with a beam profile correction was applied. 47 The structures were solved by direct methods 48 (6-PF6 and 10) or with SHELXT 49 (2-PF6 and 3-PF6) and were refined by full-matrix least-squares on all unique F 2 values, [48] [49] [50] with anisotropic displacement parameters for all non-hydrogen atoms, and with constrained riding hydrogen geometries; Uiso(H) was set at 1.2 (1.5 for methyl groups) times Ueq of the parent atom. The largest features in final difference syntheses were close to heavy atoms and were of no chemical significance.
CrysAlis
Pro was used for control and integration, 47 and SHELX 48 and OLEX2 51 were employed for structure solution and refinement. ORTEP-3 52 and POV-Ray 53 were employed and for molecular graphics. Crystallographic data are reported in Table S2 . CCDC 1855896-1855899 contain supplementary crystal data for this article.
Cell viability Assay
The human lung epithelial cancer cells A549, the human ovarian cancer cells SKOV-3, the 
ESI mass spectrometry
Horse heart cytochrome c (cyt c) was purchased from Sigma (code C7752 Holliston, USA). Before sample injection, the capillary was rinsed with BGE for 1 min. Samples were injected hydrodynamically for 5 s at 50 mbar. Typical instrument parameters can be found in Table 4 . ESI-MS data were analyzed and processed using ESI Compass 1.3 
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A new series of novel (C^N^N) cyclometalated gold(III) complexes have been characterized for their structural and spectroscopic properties. The compounds anticancer activities have been studied in vitro and their reactivity with model biomolecules has been elucidated by mass spectrometry techniques, evidencing an unexpected preference for binding to nucleic acids with respect to proteins and amino acids.
